Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal

Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. RVNC. Under the terms of the agreement, Crown will commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share in cash, representing a total enterprise value of $924 million. The purchase price represents a premium of 89% over Revance's closing market price on Aug. 9, 2024, and a 111% premium to Revance's 60-day volume-weighted average ...